Letters to the Editor
Mepolizumab for refractory eosinophilic fasciitis: a retrospective analysis from two tertiary care centres
S.N. Sanchez-Melendez1, K.S. Shaw2, C.X. Pan3, D.L. Taylor4, N. Shahriari5, D.R. Mazori6, R.A. Vleugels7
- Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA, and Ponce Health Sciences University, School of Medicine, Ponce, Puerto Rico.
- Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
- Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
- Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
- Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
- The Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, New York, NY, USA.
- Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. rvleugels@bwh.harvard.edu
CER16650
2023 Vol.41, N°8
PI 1721, PF 1722
Letters to the Editor
Free to view
(click on article PDF icon to read the article)
PMID: 37246772 [PubMed]
Received: 06/03/2023
Accepted : 17/04/2023
In Press: 25/05/2023
Published: 03/08/2023
